Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388889 · ClinicalTrials.gov registry record · Phase 3
Phase III Long-Term Extension Study With Dexpramipexole
A Phase 3 study, sponsored by Areteia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 509
- Enrollment target
NCT06388889: Clinical Trial Phase 3 study, sponsored by Areteia Therapeutics.
NCT06388889 is a Phase 3 study that was terminated before completion, run by Areteia Therapeutics. The registered enrollment target is 509 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06388889, a Phase 3 study, was terminated before completion, sponsored by Areteia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 509 participants
- Enrollment target
Study Summary
The goal of this clinical trial\] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 \[GINA, 2021\] Step 4 or 5 therapy and who completed either of the Phase III studies EXHALE-2 or EXHALE-3.
Primary Outcome
Summary of participants from the safety population who experienced an adverse event.
Interventions
- DRUG Dexpramipexole Dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 3 |
Why NCT06388889 stopped before completion
NCT06388889 is an interventional study that assigns participants to a tested intervention. The registered 509 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 1 intervention - of which Dexpramipexole Dihydrochloride is the first listed.
NCT06388889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06388889 about?
NCT06388889 is a clinical study titled "Phase III Long-Term Extension Study With Dexpramipexole". The goal of this clinical trial\] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 \[GINA, 2021\] Step 4 or 5 therapy and who completed either of the Phase III studies EXHALE-2 or EXHALE-3.
What is the current status of trial NCT06388889?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 509 participants. The study started on 2024-06-12. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT06388889?
The interventions under investigation include: Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT06388889?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06388889's enrollment target sits among peer trials
509 737th of 2000 higher than 1,264 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI